Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University, The Netherlands.
Neurobiol Dis. 2011 Jan;41(1):104-10. doi: 10.1016/j.nbd.2010.08.026. Epub 2010 Sep 15.
Pharmaceutical treatments are being developed to correct specific behavioural and morphological aspects of neurodevelopmental disorders such as mental retardation. Fragile X syndrome is an X-linked mental retardation with abnormal dendritic protrusions from neurons in the brain. Increased signalling via excitatory metabotropic glutamate receptor (mGluR) pathways is hypothesised to contribute to this disorder. Targeting these receptors has shown improvements in both behaviour and morphology with the Fmr1-KO mouse model for the syndrome. It is not known whether similar changes occur in excitatory synaptic activity following treatment with mGluR antagonists. We tested the effects of prolonged mGluR blockade on excitatory synaptic activity at three developmental time points in hippocampal slices. We observed a rescue effect of the antagonist MPEP upon spontaneous EPSC amplitude and charge at 2 weeks but not 1 week or 8-10 weeks of development. These data support the role of mGluR antagonist treatment for functional synaptic correction at an early developmental stage in a model for fragile X syndrome.
正在开发药物治疗方法来纠正神经发育障碍的特定行为和形态方面,例如智力迟钝。脆性 X 综合征是一种 X 连锁智力迟钝,其大脑神经元中的树突突起异常。兴奋性代谢型谷氨酸受体(mGluR)途径的信号增加被假设为导致这种疾病的原因。针对这些受体的治疗方法显示出与该综合征的 Fmr1-KO 小鼠模型相关的行为和形态改善。目前尚不清楚在使用 mGluR 拮抗剂治疗后,兴奋性突触活动是否会发生类似的变化。我们在海马切片中三个发育时间点测试了长期 mGluR 阻断对兴奋性突触活动的影响。我们观察到拮抗剂 MPEP 在 2 周但不在 1 周或 8-10 周时对自发 EPSC 幅度和电荷量有挽救作用。这些数据支持在脆性 X 综合征模型中,mGluR 拮抗剂治疗在早期发育阶段对功能性突触矫正的作用。